申请人:The United States of America, as represented by the Secretary, Department of Health and Human
公开号:US20210323941A1
公开(公告)日:2021-10-21
The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R
1
, R
2
, R
3
, and R
4
are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.